OREGA Biotech – meet us at BIO-Europe 2019, Nov. 11 & 12
Lyon, France, September 23, 2019 – OREGA Biotech will participate in the upcoming BIO-Europe conference to be held in Hamburg, Germany, on November 11-13, 2019. BIO-Europe is Europe’s largest partnering conference serving the global biotech industry. OREGA Biotech will actively take part in this business event to promote our partnership-driven business model based on our in vivo screening platform aiming at discovering novel immune checkpoints and regulators of anti-PD1 response. Building on the successful partnering of our anti-CD39 antibodies (licensed to Innate Pharma and now partnered with AstraZeneca), we are open to discussion for our new program related to the discovery of a novel regulator of anti-PD1 response.
Jeremy Bastid, Chief Operating Officer, will attend the BIO-Europe conference on November 11 & 12, 2019.
About OREGA Biotech
OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. Our in vivo screening platform aims at discovering and validating novel immune checkpoints and regulators of anti-PD1 response. Anti-CD39 antibody were licensed to Innate Pharma in 2016 and have been further partnered with AstraZeneca in 2018. Incepted in 2010, OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our business strategy is to establish preclinical proof of concept with our targets prior entering into early stage partnership or license agreements with larger biotech or pharmaceutical companies. The company is managed by Gilles Alberici, CEO and Jeremy Bastid, COO.
For more information: www.orega-biotech.com